BRAF and cholangiocarcinoma: In the phase II, multicenter basket trial (NCT02034110), the combination of dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) was tested in patients with advanced CCA harboring the BRAF V600E mutation who had progressed following standard therapies, including 39 cases of iCCA.